Denmark courts disillusioned Americans with new Copenhagen drive
The authorities in Denmark's capital are launching the "Come to Us" campaign, aiming to attract educated U.S. citizens who may be disillusioned with Donald Trump's victory in the presidential elections.
5:18 PM EST, November 11, 2024
Copenhagen's officials announced on Monday the launch of the "Come to Us" campaign, which seeks to encourage highly qualified Americans to move and work in the city. "We hope that Americans will join talents from other countries who are already contributing to innovation and economic growth in Copenhagen," emphasized Jens-Kristian Lutken, a member of the city's employment and integration board.
"Many Americans have the education that can help us"
The campaign will be led by Capacity Copenhagen, an organization responsible for promoting entrepreneurship in the city. It will focus on modern technology, life sciences, and green transformation sectors. "We know that many Americans have the education that can help us," stated Asbjoern Overgaard, head of the organization, in a press release cited by the media.
The campaign will also highlight the benefits of working in Denmark, such as maintaining a work-life balance, a flat hierarchical company structure, and extensive social security. Danish vacations are significantly longer than in the U.S., providing an additional draw for potential immigrants.
Danes showed strong support for Kamala Harris
About 11,500 American citizens or people of American descent live in Denmark, with two-thirds residing in the Copenhagen region. City authorities hope the initiative will increase this number.
According to Gallup Institute studies, Danish society showed the greatest support for Democratic candidate Kamala Harris among European countries. If Danes could decide the outcome of the U.S. presidential elections, 85% would vote for Harris, while only 4% would support Trump.
Novo Nordisk, headquartered near Copenhagen, produces diabetes and obesity drugs like Ozempic and Wegovy. It is among the highest-valued firms in Europe and the third-largest pharmaceutical company in the world by value.